Better immune and targeted radiation treatment for head and neck cancer
Optimizing immunoradiotherapy for HNSCC
This research tests whether protecting nearby lymph nodes during focused radiation together with PD‑1 immunotherapy helps people with head and neck squamous cell carcinoma, especially HPV‑negative tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11144432 on NIH RePORTER |
What this research studies
If you have head and neck squamous cell carcinoma, this project combines PD‑1 immune drugs with small, focused radiation aimed at the tumor while trying to spare the draining lymph nodes that help trigger immune responses. Early lab and animal work showed that damaging or removing these lymph nodes can stop PD‑1 drugs from working, so the team will use lymphatic‑sparing stereotactic radiation and monitor tumor outcomes. Researchers will track immune cells such as dendritic cells and B cells in the nodes and blood and record side effects and tumor control. The work includes both laboratory studies explaining how lymph nodes support anti‑tumor immunity and early‑phase patient treatment using the combined approach.
Who could benefit from this research
Good fit: Ideal candidates are adults with head and neck squamous cell carcinoma who are eligible for PD‑1 therapy and for focused stereotactic radiation, particularly those with HPV‑negative disease.
Not a fit: People without head and neck squamous cell carcinoma, those not eligible for PD‑1 drugs or stereotactic radiation, or those whose care requires standard large‑field radiation or extensive surgery are unlikely to benefit directly.
Why it matters
Potential benefit: If successful, this approach could increase the number of patients who respond to PD‑1 immunotherapy and reduce harm from large-field radiation or unnecessary lymph node removal.
How similar studies have performed: PD‑1 immunotherapy has shown modest response rates (around 14–20%) and a Phase III trial found no benefit when added to standard large‑field chemoradiation, so lymph‑node‑sparing immunoradiotherapy is a newer strategy supported by early‑phase clinical work and preclinical data.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Califano, Joseph a — University of California, San Diego
- Study coordinator: Califano, Joseph a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.